TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood TO 
THE EDITOR
TEL-AML1 fusion resulting from the cryptic translocation t(12;21)(p13;q22) constitutes the most frequent genetic rearrangement in initial childhood B cell precursor (BCP) acute lymphoblastic leukemia (ALL) (20-25%), and has been associated with a favorable prognosis in life-table analyses assessing outcome at 3 or 4 years. [1] [2] [3] [4] In contrast, the communicated incidences of TEL-AML1 positivity in relapsed ALL either supporting or questioning the feature of TEL-AML1 fusion as positive prognostic indicator vary strongly. In a recent issue of Leukemia, Zuna et al 5 and Rubnitz et al 6 reported on the incidence of TEL-AML1 fusion in relapsed childhood ALL treated initially on ALL BFM (Berlin-Frankfurt-Mü nster) protocols 83 to 95 in the Czech Republic, and on three consecutive protocols at St Jude Children's Hospital, respectively. Four out of 45 relapsed ALL were TEL-AML1 positive in the Czech study (8.9%) and 5/49 (10.2%) in the analysis of St Jude. This incidence is lower than in previous Japanese and German reports (19-28%). [7] [8] [9] In yet another recent retrospective study, the DFCI study group found an exceedingly low incidence of relapsed TEL-AML1-positive ALL (1/32, 3.1%). 10 These variable frequencies (3.1-28%) require comment at this point and clarification in prospective clinical trials.
General characteristics of TEL-AML1-positive childhood ALL both at diagnosis and at relapse are the restriction to B cell precursor immunophenotype, good response to current combination chemotherapy, and mostly WBC Ͻ50 × 10 3 l. [2] [3] [4] [5] [6] [8] [9] [10] In spite of different relapse rates, studies on relapsed TEL-AML1-positive BCP-ALL are concordant with respect to the long median duration of first complete remission (CR). 5, 6, [8] [9] [10] Major points of criticism regarding these retrospective studies on frequency of TEL-AML1 in first BCP-ALL relapses concern selection biases due to retrospective analysis of cryopreserved bone marrow samples, and analysis of only a small cohort of patients treated furthermore on consecutive frontline regimens. Methodological aspects and -although very unlikely -therapy-induced secondary leukemia possibly influencing the relapse rates cannot be ruled out completely at present.
In addition to our previous report on 142 patients with relapsed BCP-ALL, 9 bone marrow samples from a total of 268 children with first BCP-ALL relapse enrolled in multicentric BFM study group relapse trials, ALL-REZ BFM 90/96, including 178 patients screened prospectively during the last 2. years, were analyzed for the presence of TEL-AML1 fusion transcripts. Chimeric TEL-AML1 transcripts were detected by nested RT-PCR, and integrity of cDNA was controled by internal co-amplification of c-ABL cDNA, as described previously. To confirm results, one additional diagnostic sample was analyzed separately. Methodology of nested RT-PCR was verified by interphase FISH analysis of 25 TEL-AML1-positive and 58 TEL-AML1-negative ALL samples. Results were in complete concordance in all comparative analyses.
The frequency of TEL-AML1 positivity in first BCP-ALL relapses was 17.5% (50/268) in the total study population, and 17.4% (31/178) in the prospective analysis. The predominant majority of patients ana- TEL-AML1-negatives were assigned to the high risk group. No significant differences were detected in all analyses between TEL-AML1 defined groups regarding WBC and peripheral blast cell count, sex, and age at relapse. The rather high incidence of TEL-AML1 fusion in second BCP-ALL relapses may be biased in the way that not all second relapses are reported to the study center, and that TEL-AML1 are overrepresented due to association of late-relapse and better outcome.
Considering all published reports, irrespective of frontline treatment and size of study cohort TEL-AML1-positive BCP-ALL are characterized by a long duration of first CR (median 46 months; range 13-125 months). 5, 6, [8] [9] [10] Half of the patients suffer a relapse beyond 46 months of diagnosis. Therefore, analyses of frontline treatment assessing outcome at 3 to 4 years omit half of all relapse events. This accounts also to survival analyses only including patients with ALL at risk beyond 4 years. 5 Moreover, in order to prevent biases based on dissimilar distribution of ALL immunophenotypes and/or low number of patients prone to marked variations, the incidence of TEL-AML1 fusion should be related to B cell precursor phenotype. An additional relapse in the study of Zuna et al 5 would increase the relapse rate of TEL-AML1-positive ALL among BCP-ALL from 13.3% (4/30) to 16.1% (5/31), an incidence similar to the presented results based on a representative number of patients with BCP-ALL. Concerning the St Jude study, the immunophenotypes of the analyzed ALL were not specified. 6 Prospective data are lacking from other single or multicentric centers. However, the discrepancies on frequency of TEL-AML1 fusion at ALL relapse clearly demonstrates that many issues remain to be resolved in prospective clinical trials on sufficiently large cohorts. Evaluation of both frontline and relapse studies have to take into account the long relapse-free intervals of TEL-AML1-positive patients. The international comparison of different frontline trials will permit evaluation of the effect and efficacy of therapeutic regimens in the treatment of TEL-AML1-positive ALL.
Significance of the TEL-AML fusion gene in childhood AML

TO THE EDITOR
We agree with Seeger and colleagues that large prospective studies of consecutive newly diagnosed ALL cases are needed to definitively determine the prognostic significance of the TEL-AML1 fusion. While Seeger and colleagues have now confirmed their previous report 1 of a high frequency of TEL-AML1 positivity among cases of B cell precursor ALL in first relapse, they also note the wide variation in frequencies reported in the literature (3-28%). In our analysis of relapsed childhood ALL cases, 10.2% (five of 49) expressed TEL-AML1. 2 Even if we limit our analysis to cases with a B cell precursor phenotype, the frequency only increases to 10.8% (five of 46 cases).
We have previously reported a favorable prognosis associated with the TEL-AML1 fusion in ALL cases treated at our center. In a study of ALL cases treated on the St Jude Total XII protocol, we molecularly analyzed 170 of 188 cases (90%), including 138 of 146 (95%) of B precursor ALL. 3 Only two relapses were observed among 30 TEL-AML1-positive cases. 3 In a recent update, we have demonstrated that the 10-year cumulative incidence of relapse was only 9 ± 5% for TEL-AML1-positive cases, with all relapses occurring more than 3 years from diagnosis. 2, 4 Notwithstanding the excellent treatment results for TEL-AML1-positive cases in our and other studies, 5, 6 we must remember that treatment efficacy is the important prognostic factor that can alter the clinical significance of genetic alterations. For example, one study of childhood ALL demonstrated that TEL-AML1-positive patients treated with a non-intensive antimetabolite-based regimen had a 5-year disease-free survival rate of only 55 ± 15%, compared to a rate of 100% in those treated on a more intensive contemporary protocol. 7 We suggest that all newly diagnosed ALL cases be screened for the TEL-AML1 fusion and that these patients receive risk-adapted therapy and suitable monitoring. In our current ALL trial, TEL-AML1-positive patients are provisionally assigned to the low-risk arm at diagnosis and receive intensified antimetabolite-based therapy. However, patients with a slow early response to therapy or with detectable minimal residual disease (Ͼ1 × 10 −4 ) at the end of induction are assigned to the more intensive standard-risk therapeutic arm. Future studies will focus on defining the optimal therapy for TEL-AML1 leukemia to further improve cure rates and decrease treatment-related morbidity.
